New ATMP guidance: Characterisation of the Capsid Particle Population for rAAV Products

With complexity and risk associated with each stage of assay development, our Advanced Therapy Medicinal Products (ATMP) Characterisation of the Capsid Particle  Population for rAAV Products best practice guidance offers a toolbox of appropriate methods to help during assay development. 

This new guidance has been developed and approved by the British Pharmacopoeia (BP), as part of the MHRA, in partnership with experts from the cell and gene therapy community including industry, the NHS and academia. 

Available as part of the BP online and free to download, our new ATMP guidance supports the ATMP community to standardise operations and feel confident to do their job more effectively.   

Find out more or download a free sample copy